Skip to main content
. Author manuscript; available in PMC: 2022 Jan 11.
Published in final edited form as: Mol Pharm. 2021 Jul 14;18(8):2889–2905. doi: 10.1021/acs.molpharmaceut.1c00455

Figure 1.

Figure 1.

The fate of nanoparticles in tumor tissues. Nanoparticles entered tumor tissues from blood vessel through enhance penetration and retention (EPR) effects, then reach tumor cells through penetration, and finally are endocytosed by cancer cells.